Global Overactive Bladder Therapeutics Market Is Estimated To Witness Significant Growth Due To Increasing Geriatric Population And Growing Frequency Disorders

Overactive Bladder Therapeutics Market
Overactive Bladder Therapeutics Market 

Overview:

Symptomatic overactive bladder, also known as urge urinary incontinence, is a common condition affecting 12-17% of the population. It can have significant consequences for quality of life, including work, social activities, exercise and sleep. First-line treatment includes lifestyle interventions, pelvic floor exercises, bladder training and antimuscarinic agents. When these are not effective, urology referral is necessary. Second-line therapy involves invasive treatments such as botulinum toxin, neuromodulation or surgical procedures such as augmentation cystoplasty or urinary diversion.

These therapies can help alleviate symptoms and improve the quality of life. Third-line therapies are based on more recent data and include intradetrusor injection of onabotulinumtoxinA, peripheral tibial nerve stimulation and sacral neuromodulation. Fourth-line therapy is also considered for patients with refractory OAB and includes the use of augmentation cystoplasty or urinary diversion. Medication side effects can be more of an issue for older patients or those with other medical problems, such as high blood pressure or memory loss.

Market Dynamics:

Increasing research and developmental activities are estimated to augment growth of the global Overactive Bladder Therapeutics Market over the forecast period. For instance, Urovant Sciences, presented the data of their Phase 3 EMPOWUR Extension Study of GEMTESA in May 2022. This study will confirm the durability and potential utility in patient population and examine their long-term effects. Moreover, increasing product recalls are anticipated to restrain growth of the global overactive bladder therapeutics for market over the forecast period.

Impact of COVID-19:

The pandemic was first recognized in 2019 in China and in 2020 it was declared as a public health emergency. The pandemic affected the demand and production of several markets. Many countries like Spain, Italy, France, India, China and many more implemented strict lockdowns for preventing further spread off the virus. This led to shutting down of manufacturing units, and factories. 

Supply chains were also disrupted owing to the pandemic. Thus, there was a shortage of raw materials in various industries. This hampered the demand for overactive bladder therapeutics. Thus, the global Overactive Bladder Therapeutics Market was affected in a negative manner due to the pandemic.

Key Takeaways:

The global Overactive Bladder Therapeutics Market is expected to witness high growth, exhibiting CAGR of 3.6 % over the forecast period, due to rising product launches.

For instance, Fesoterodine fumarate extended-release tablets, were introduced by Dr. Reddy’s Laboratories in July 2022. These tablets are a therapeutic generic equivalent to Toviaz by Pfizer in the US for treating overactive bladder.

North America is anticipated to witness significant growth in the global overactive bladder therapeutics for market over the forecast period, owing to well-developed healthcare infrastructure.

Major players operating in the global Overactive Bladder Therapeutics Market are Hugel, AbbVie, Bayer AG, Astellas Pharma, Laborie, Intas Pharmaceuticals, Endo International PLC, Glenmark, Hisamitsu Pharmaceutical, Sun Pharmaceutical, Johnson & Johnson Services, Uro Medical, Medtronic, Lupin, Pfizer, Urovant Sciences, Sanofi, Macleods Pharmaceuticals, Viatris, Hisamitsu, and Teva Pharmaceutical.

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Bioresorbable Implants Can Also Help To Prevent Complications And Speed Up The Recovery Process

Image
Bioresorbable Implants Medical implants, either passive for structural support or for diagnosis and therapy with active electronics, are widely used in surgical applications. Although they have shown long-term biocompatibility, their removal imposes physical, biological and economical burdens on patients. To overcome this drawback, implantable devices exhibiting biodegradation in the body have been developed. These implants disappear inside the body after a certain time of use, and can be replaced with natural bone. The resorption of Bioresorbable Implants is driven by hydrolysis of the bonds linking their monomers. The amorphous portions of the polymer degrade first, while the crystalline regions remain intact and provide most of their mechanical strength. The monomers are then broken down into lactic and glycolic acids, which are converted to pyruvate and then processed through the citric acid cycle into water and carbon dioxide. The Bioresorbable Implants Market was valued at US$
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more